Verona Pharma Appoints Kathleen Rickard, MD, as Chief

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
90
Verona Pharma Appoints Kathleen Rickard, MD, as Chief Medical Officer to Lead Late Stage Clinical Development of RPL554

LONDON, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq: VRNA ) (“Verona Pharma”), a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces the expansion of its global clinical development team with the appointment of Kathleen Rickard, MD, as Chief Medical Officer, and Tara Rheault, PhD, MPH, as Vice President of Research and Development Operations and Global Project Management. Drs. Rickard and Rheault will be based in the Company’s U.S. offices from where they will leverage their expertise to help drive global R&D activities. Dr. Rickard is expected to start in her role on February 1, 2019 and Dr. Rheault started in her role on January 1, 2019.

In her new role, Dr. Rickard brings 25 years of experience in clinical research in respiratory medicine, industry, and management to lead the clinical development of RPL554, Verona Pharma’s first-in-class product candidate in development for the maintenance treatment of chronic obstructive pulmonary disease (“COPD”), cystic fibrosis (“CF”), and potentially asthma.  

“We are delighted to welcome Drs. Rickard and Rheault to Verona Pharma and look forward to working with them to advance RPL554 into late stage clinical development,” said Jan-Anders Karlsson, PhD, CEO of Verona Pharma. “Dr. Rickard’s extensive expertise in respiratory drug development combined with her strong leadership skills will be a tremendous asset as we prepare for the pivotal Phase 3 clinical development program for the maintenance treatment of COPD. Likewise, Dr. Rheault’s years of experience at the intersection of clinical development, regulatory affairs and commercialization will help guide our global R&D and project management efforts.”

Prior to joining Verona Pharma, Dr. Rickard served in multiple roles at Aerocrine AB and subsequently Circassia, where she was instrumental in directing clinical and regulatory strategies for NIOX VERO, an airway inflammation test for managing asthma, across key markets such as the United States, China, and Japan, as well as the rest of the world.  Previously, Dr. Rickard was Vice President Clinical Development and Medical Affairs of GlaxoSmithKline’s Respiratory Medicines Development Centre and, over a period of 15 years, held a number of other leadership positions in clinical development across GlaxoSmithKline’s global respiratory franchise.

Dr. Rheault has more than 16 years of cross-functional leadership experience across drug discovery and development. Prior to joining Verona Pharma, she was a strategic drug development leader at IQVIA where she helped pharmaceutical companies develop integrated commercial and R&D strategies, including work on the Company’s RPL554 program. Dr. Rheault started her career as a medicinal chemist at GlaxoSmithKline, where she was the inventor of the now marketed drug Tafinlar ® . She then moved on to global project leadership and portfolio management for early development projects, building integrated early R&D and commercial strategies for new dermatology products, before transitioning into late stage clinical development in the respiratory therapy area as a clinical program and study leader, contributing to Nucala, Incruse, Breo and Anoro late stage development programs, in addition to other novel programs.

About Verona Pharma plc Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. Verona Pharma’s product candidate, RPL554, is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. In previous clinical trials, RPL554 has been observed to result in bronchodilator effects when used alone or as an add-on treatment to other COPD bronchodilators. It has shown clinically meaningful and statistically significant improvements in lung function when administered in addition to frequently used short- and long-acting bronchodilators, such as tiotropium (Spiriva ® ), compared with such bronchodilators administered as a single agent. RPL554 improved FEV 1 over four weeks in patients with moderate-to-severe COPD when compared to placebo and improved COPD symptoms and quality of life in a Phase 2b multicenter European study performed in 403 patients. In addition, RPL554 has shown anti-inflammatory effects in a standard challenge study with COPD-like inflammation in human subjects. RPL554 has been well tolerated in these studies and has shown a favorable safety and tolerability profile, having been administered to more than 730 subjects in 12 clinical trials. Verona Pharma is developing RPL554 for the treatment of COPD, CF, and potentially asthma.

Forward-Looking Statements This press release contains forward-looking statements. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding Drs. Rickard and Rheault’s roles at Verona Pharma and their potential contributions to the development of RPL554, including into late stage development.

These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from our expectations expressed or implied by the forward-looking statements, including, but not limited to, the following: our limited operating history; our need for additional funding to complete development and commercialization of RPL554, which may not be available and which may force us to delay, reduce or eliminate our development or commercialization efforts; the reliance of our business on the success of RPL554, our only product candidate under development; economic, political, regulatory and other risks involved with international operations; the lengthy and expensive process of clinical drug development, which has an uncertain outcome; serious adverse, undesirable or unacceptable side effects associated with RPL554, which could adversely affect our ability to develop or commercialize RPL554; potential delays in enrolling patients, which could adversely affect our research and development efforts; we may not be successful in developing RPL554 for multiple indications; our ability to obtain approval for and commercialize RPL554 in multiple major pharmaceutical markets; misconduct or other improper activities by our employees, consultants, principal investigators, and third-party service providers; material differences between our “top-line” data and final data; our reliance on third parties, including clinical investigators, manufacturers and suppliers, and the risks related to these parties’ ability to successfully develop and commercialize RPL554; and lawsuits related to patents covering RPL554 and the potential for our patents to be found invalid or unenforceable. These and other important factors under the caption “Risk Factors” in our Annual Report on Form 20-F filed with the Securities and Exchange Commission (“SEC”) on February 27, 2018, and our other reports filed with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

For further information, please contact:

Verona Pharma plc Tel: +44 (0)20 3283 4200
Jan-Anders Karlsson, Chief Executive Officer info@veronapharma.com  
   
Stifel Nicolaus Europe Limited (Nominated Adviser and UK Broker) Tel: +44 (0) 20 7710 7600
Stewart Wallace / Jonathan Senior / Ben Maddison  
   
FTI Consulting (UK Media and Investor enquiries) Tel: +44 (0)20 3727 1000
Simon Conway / Natalie Garland-Collins veronapharma@fticonsulting.com  
   
ICR, Inc. (US Media and Investor enquiries)  
Darcie Robinson Tel: +1 203-919-7905 Darcie.Robinson@icrinc.com
Stephanie Carrington Tel. +1 646-277-1282 Stephanie.Carrington@icrinc.com

 

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 180

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading
Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 154

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 71

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 157

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Epic Blue Puts $50,000 of Marketing Work to Use Locally

Updated Category News Views 136

A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 154

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 27

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 93

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 129

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
Maryland Handgun Ban Suit Puts Ruger in Legal Crossfire

Updated Category News Views 150

A January Deadline With Real Commercial Teeth Maryland has turned a trigger-design dispute into a fresh legal and retail headache, and the clock is not polite about it. The National Shooting Sports Foundation filed suit against the state over S.B. 334, which is scheduled to take effect Jan. 1, 2027. The law bars sales of certain pistols with cruciform trigger bars,...

Continue Reading

Top 5 Most Recently Viewed Articles

Avaline's Organic Wines Shine in New Holiday Campaign

Updated Category News Views 250

Avaline Unveils Its Charming Holiday Campaign The organic wine brand Avaline is excited to kick off its holiday campaign, which beautifully captures the spirit of the season. By blending nostalgia with festive cheer, Avaline invites everyone to relish the little moments that make the holidays special. The campaign draws inspiration from beloved holiday films, reminding us...

Continue Reading
Exploring In-Game Advertising: Key Insights for Brands

Updated Category News Views 206

Unlocking the Potential of In-Game Advertising Recent research conducted by Cint sheds light on the rising value of in-game advertising (IGA) for brands and the necessity for measurement standards within this dynamic marketing field. Video games have increasingly become a vital platform for advertisers, offering rich engagement opportunities. Consumers are showing...

Continue Reading
Mawson Infrastructure Reports Significant Operational Growth

Updated Category News Views 66

Update on Mawson Infrastructure Group's Operations Mawson Infrastructure Group Inc. recently released a significant operational update that highlights impressive growth in its digital colocation sector. The figures show a remarkable 166% increase in digital colocation revenue compared to a year ago, specifically in August 2023, and a solid 25% growth from the previous...

Continue Reading
Cybersecurity Landscape Evolves: New Threats and Insights

Updated Category News Views 292

An Overview of Current Cybersecurity Threats The digital landscape is becoming increasingly complex, and organizations are challenged with new and emerging cybersecurity threats. Red Canary's recent report dives deep into these threats, highlighting alarming trends that security teams must address now. The Rise of Identity Attacks As technology continues to advance, so do...

Continue Reading
US Family Health Plan Brighton Marine Celebrates Recognition with Awards

Updated Category News Views 188

US Family Health Plan Brighton Marine Honored with Excellence Awards Recent accolades reflect the dedication and quality of care provided by US Family Health Plan Brighton Marine. This esteemed organization has been awarded three Human Experience Pinnacle of Excellence Awards, recognizing it as one of the top health plans across the nation. Such recognition highlights the...

Continue Reading